Encompass Health Maintains 2025 Guidance: Adjusted EBITDA $1.185-$1.220 Billion, Adjusted EPS $4.85-$5.10

Reuters
06-04
Encompass Health Maintains 2025 Guidance: Adjusted EBITDA $1.185-$1.220 Billion, Adjusted EPS $4.85-$5.10

Encompass Health Corporation has reiterated its financial outlook for the full year 2025. The company forecasts net operating revenue between $5,850 million and $5,925 million. Adjusted EBITDA is expected to range from $1,185 million to $1,220 million. Additionally, the company projects adjusted earnings per share from continuing operations attributable to Encompass Health to be between $4.85 and $5.10. The company has refrained from providing guidance on a GAAP basis, except for net operating revenues, due to the unpredictability of certain external factors that could impact its financial results. These include various settlements, professional fees, and other items not indicative of ongoing performance. However, for 2025, Encompass Health estimates interest expense and amortization of debt discounts and fees to be approximately $125 million, and amortization of debt-related items to be around $10 million. Members of the company's senior management team are scheduled to meet with investors and analysts in June 2025 to discuss these projections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Encompass Health Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000785161-25-000028), on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10